RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cue Biopharma Stock

Cue Biopharma Employees 2025

Cue Biopharma Employees

50

Ticker

CUE

ISIN

US22978P1066

WKN

A2JAT5

In 2025, Cue Biopharma employed 50 people, a 0% change from the 50 number of employees in the previous year.

Cue Biopharma Aktienanalyse

What does Cue Biopharma do?

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years. Cue Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Cue Biopharma's Employee Base

Cue Biopharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Cue Biopharma's operational capacity and future potential.

Year-to-Year Comparison

Assessing Cue Biopharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Cue Biopharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Cue Biopharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Cue Biopharma stock

How many employees does Cue Biopharma have this year?

Cue Biopharma has 50 undefined employees this year.

How many employees did Cue Biopharma have compared to the previous year?

Compared to the previous year, Cue Biopharma had 0% more employees.

What impact did the number of employees have on the company Cue Biopharma?

The number of employees has a direct impact on the efficiency and productivity of Cue Biopharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Cue Biopharma?

The number of employees can also have an impact on investors of Cue Biopharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Cue Biopharma affect the company?

An increase in equity of Cue Biopharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Cue Biopharma's equity affect the company?

A reduction in equity of Cue Biopharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Cue Biopharma?

Some factors that can influence the equity of Cue Biopharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Cue Biopharma so important for investors?

The equity of Cue Biopharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Cue Biopharma influence the company?

The number of employees at Cue Biopharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Cue Biopharma evolved in recent years?

In recent years, the number of employees at Cue Biopharma has changed by 0.

How many employees does Cue Biopharma currently have?

Cue Biopharma currently has 50 undefined employees.

Why is the number of employees important for investors of Cue Biopharma?

The number of employees is important for investors of Cue Biopharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Cue Biopharma take to change the number of employees?

To change the number of employees, Cue Biopharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Cue Biopharma pay?

Over the past 12 months, Cue Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cue Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Cue Biopharma?

The current dividend yield of Cue Biopharma is .

When does Cue Biopharma pay dividends?

Cue Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cue Biopharma?

Cue Biopharma paid dividends every year for the past 0 years.

What is the dividend of Cue Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cue Biopharma located?

Cue Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cue Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cue Biopharma from 1/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/5/2025.

When did Cue Biopharma pay the last dividend?

The last dividend was paid out on 1/5/2025.

What was the dividend of Cue Biopharma in the year 2024?

In the year 2024, Cue Biopharma distributed 0 USD as dividends.

In which currency does Cue Biopharma pay out the dividend?

The dividends of Cue Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cue Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cue Biopharma

Our stock analysis for Cue Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.